Pharmafile Logo

eribulin

- PMLiVE

Merck’s Keytruda receives NICE recommendation as breast cancer treatment option

Patients will now be able to access immunotherapy at an earlier stage in their treatment journey

- PMLiVE

NHS reports rise in prostate cancer treatments in England

Prostate Cancer UK’s risk checker has been used over a million times since its launch in February

- PMLiVE

QiC Diabetes awards 2022 celebrate UK healthcare excellence

The annual awards recognise the efforts of NHS teams and individuals

- PMLiVE

NHS to roll out brain laser therapy for epilepsy patients

There are around 600,000 people living with epilepsy across the UK

- PMLiVE

NICE recommends Grifols’ Tavlesse for chronic immune thrombocytopenia

Patients with chronic ITP may live with an increased risk of severe bleeding events

- PMLiVE

Charac teams up with NPA to expand role of independent pharmacies

The organisations aim to boost digital transformation for online pharmacy services

- PMLiVE

Bristol Myers Squibb’s active ulcerative colitis treatment bags NICE recommendation

Phase 3 trial results of Zeposia showed statistically significant results in response and remission

- PMLiVE

Biogen and Eisai’s lecanemab shows promise in confirmatory Alzheimer’s study

Results from the phase 3 trial showed reduction in clinical decline

- PMLiVE

Merck bags NICE recommendation for renal cell carcinoma adjuvant treatment

Patients will now be able to access immunotherapy at an earlier stage in their treatment pathway

- PMLiVE

BeiGene’s Brukinsa gets green light from NICE as Waldenström’s macroglobulinemia treatment

The condition occurs in less than 2% of patients with non-Hodgkin lymphomas

- PMLiVE

NICE rejects AstraZeneca and MSD’s Lynparza as NHS prostate cancer treatment

The drug will not be available as a treatment option for men with prostate cancer in England and Wales

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links